🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist

    Pharma Mar S.A.

    Cancer

    phase 2 small molecule active

    1 trial

  2. LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab

    Pharma Mar S.A.

    Melanoma

    phase 2 small molecule active

    1 trial

  3. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Pharma Mar S.A.

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod

    Pharma Mar S.A.

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  5. LUMYKRAS 120 mg film-coated tablets, LUMYKRAS 240 mg film-coated tablets

    Pharma Mar S.A.

    Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  6. Lacutamab

    Pharma Mar S.A.

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  7. Letybo® 50 Einheiten Pulver zur Herstellung einer Injektionslösung, Letybo 50 Einheiten Pulver zur Herstellung einer Injektionslösung

    Pharma Mar S.A.

    Moderate and severe horizontal forehead lines.

    phase 2 small molecule active

    1 trial

  8. Leukine, OXALIPLATIN, ENDOXAN 50 mg, comprimé enrobé, STC-1010, FLUOROURACIL, CALCIUM FOLINATE

    Pharma Mar S.A.

    Unresectable locally advanced or metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  9. Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone 4 mg tablets, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets

    Pharma Mar S.A.

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. Linvoseltamab, Linvoseltamab, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Diphenhydramine Hydrochloride 25 mg Tablets, Paracetamol 500mg Tablets, REGN88, Dexamethasone 2mg Tablets

    Pharma Mar S.A.

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  11. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Pharma Mar S.A.

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  12. METRONIDAZOLE, FOSFOMYCIN, MOLGRAMOSTIM

    Pharma Mar S.A.

    Pouchitis

    phase 2 small molecule active

    1 trial

  13. MITAPIVAT

    Pharma Mar S.A.

    Sickle Cell Disease (SCD) and Nephropathy

    phase 2 small molecule active

    1 trial

  14. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, DANICOPAN, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    Pharma Mar S.A.

    Chronic spontaneous urticaria

    phase 2 small molecule active

    1 trial

  15. Meropenem-Vaborbactam

    Pharma Mar S.A.

    Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)

    phase 2 small molecule active

    1 trial

  16. NAPROXEN SODIUM, DESOGESTREL, TRAMADOL HYDROCHLORIDE, IBUPROFEN, Placebo to match AMY109, Placebo to match desogestrel, Feanolla 75 microgram film-coated tablets, CODEINE PHOSPHATE, PARACETAMOL, NAPROXEN, AMY109

    Pharma Mar S.A.

    Endometriosis

    phase 2 small molecule active

    1 trial

  17. NMD670, NMD670, Placebo

    Pharma Mar S.A.

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  18. NMD670, Placebo

    Pharma Mar S.A.

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  19. NOE-105, Placebo, Hard Capsules

    Pharma Mar S.A.

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  20. NS-229 matching tablets with no active treatment, NS-229

    Pharma Mar S.A.

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    phase 2 small molecule active

    1 trial

  21. NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pharma Mar S.A.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  22. Neflamapimod

    Pharma Mar S.A.

    Dementia with Lewy Bodies (DLB)

    phase 2 small molecule active

    1 trial

  23. Ninerafaxstat, Tablet, identical in appearance to ninerafaxstat tablets

    Pharma Mar S.A.

    Non-obstructive hypertrophic cardiomyopathy

    phase 2 small molecule active

    1 trial

  24. OCALIVA, Placebo for Bezafibrate, Bezalip Mono, Placebo for Obeticholic Acid, Bezalip, OCALIVA

    Pharma Mar S.A.

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources